These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 24298985

  • 1. Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature.
    Verkaik NJ, Hoek RA, van Bergeijk H, van Hal PT, Schipper ME, Pas SD, Beersma MF, Boucher CA, Jedema I, Falkenburg F, Hoogsteden HC, van den Blink B, Murk JL.
    Transpl Infect Dis; 2013 Dec; 15(6):E243-9. PubMed ID: 24298985
    [Abstract] [Full Text] [Related]

  • 2. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide.
    Ehlert K, Groll AH, Kuehn J, Vormoor J.
    Klin Padiatr; 2006 Dec; 218(3):180-4. PubMed ID: 16688677
    [Abstract] [Full Text] [Related]

  • 3. Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report.
    Ciszek M, Mucha K, Foroncewicz B, Chmura A, Pączek L.
    Ann Transplant; 2014 Jan 30; 19():60-3. PubMed ID: 24481271
    [Abstract] [Full Text] [Related]

  • 4. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
    Reddy AJ, Zaas AK, Hanson KE, Palmer SM.
    J Heart Lung Transplant; 2007 Dec 30; 26(12):1286-92. PubMed ID: 18096480
    [Abstract] [Full Text] [Related]

  • 5. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection.
    Avery RK, Bolwell BJ, Yen-Lieberman B, Lurain N, Waldman WJ, Longworth DL, Taege AJ, Mossad SB, Kohn D, Long JR, Curtis J, Kalaycio M, Pohlman B, Williams JW.
    Bone Marrow Transplant; 2004 Dec 30; 34(12):1071-5. PubMed ID: 15489872
    [Abstract] [Full Text] [Related]

  • 6. Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series.
    El Chaer F, Mori N, Shah D, Oliver N, Wang E, Jan A, Doan V, Tverdek F, Tayar J, Ariza-Heredia E, Chemaly RF.
    Antiviral Res; 2016 Nov 30; 135():91-96. PubMed ID: 27594527
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Trip to immunity: resistant cytomegalovirus infection in a lung transplant recipient.
    Kneidinger N, Giessen C, von Wulffen W, Milger K, Schramm R, Jäger G, Nitschko H, Striebinger H, Behr J, Neurohr C.
    Int J Infect Dis; 2014 Nov 30; 28():140-2. PubMed ID: 25267276
    [Abstract] [Full Text] [Related]

  • 9. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation.
    Battiwalla M, Paplham P, Almyroudis NG, McCarthy A, Abdelhalim A, Elefante A, Smith P, Becker J, McCarthy PL, Segal BH.
    Transpl Infect Dis; 2007 Mar 30; 9(1):28-32. PubMed ID: 17313468
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus.
    Germi R, Mariette C, Alain S, Lupo J, Thiebaut A, Brion JP, Epaulard O, Saint Raymond C, Malvezzi P, Morand P.
    Antiviral Res; 2014 Jan 30; 101():57-61. PubMed ID: 24184983
    [Abstract] [Full Text] [Related]

  • 12. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.
    Rodriguez J, Casper K, Smallwood G, Stieber A, Fasola C, Lehneman J, Heffron T.
    Liver Transpl; 2007 Oct 30; 13(10):1396-400. PubMed ID: 17902124
    [Abstract] [Full Text] [Related]

  • 13. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients.
    Mylonakis E, Kallas WM, Fishman JA.
    Clin Infect Dis; 2002 May 15; 34(10):1337-41. PubMed ID: 11981729
    [Abstract] [Full Text] [Related]

  • 14. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
    Myhre HA, Haug Dorenberg D, Kristiansen KI, Rollag H, Leivestad T, Asberg A, Hartmann A.
    Transplantation; 2011 Jul 27; 92(2):217-23. PubMed ID: 21685829
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients.
    Gagermeier JP, Rusinak JD, Lurain NS, Alex CG, Dilling DF, Wigfield CH, Love RB.
    Transpl Infect Dis; 2014 Dec 27; 16(6):941-50. PubMed ID: 25491023
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
    Iwami D, Ogawa Y, Fujita H, Morita K, Sasaki H, Oishi Y, Higuchi H, Hatanaka K, Shinohara N.
    Nephrology (Carlton); 2016 Jul 27; 21 Suppl 1():63-6. PubMed ID: 26970406
    [Abstract] [Full Text] [Related]

  • 19. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.
    Minces LR, Nguyen MH, Mitsani D, Shields RK, Kwak EJ, Silveira FP, Abdel-Massih R, Pilewski JM, Crespo MM, Bermudez C, Bhama JK, Toyoda Y, Clancy CJ.
    Antimicrob Agents Chemother; 2014 Jul 27; 58(1):128-35. PubMed ID: 24145525
    [Abstract] [Full Text] [Related]

  • 20. Leflunomide for cytomegalovirus: bench to bedside.
    Chacko B, John GT.
    Transpl Infect Dis; 2012 Apr 27; 14(2):111-20. PubMed ID: 22093814
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.